Abstract
Purpose To investigate trends in prevalence and expenditures of growth hormone (GH) use by U.S. youth in the last 15 years, a period during which FDA approved GH treatment for idiopathic short stature (ISS) and insurers imposed greater barriers to GH treatment reimbursements. Methods Using 2001-2016 OptumInsight commercial claims data, we analyzed trends in claims of GH drugs among beneficiaries aged 0-18 years (n=38,857 beneficiaries receiving GH). Outcome measures included annual prevalence of GH claims, and annual total insurer and total patient payments for GH claims. t-tests tested for linear time trends in outcomes. Percentage of beneficiaries switching GH brands also was calculated. Results Number of members with GH claims per 10,000 beneficiaries under age 18 rose steadily from 5.1 in 2001 to 14.6 in 2016, without a dramatic change around 2003, the ISS approval date. Mean total GH expenditures decreased (-26% in constant dollars), as did the estimated insurance-paid amount (-28%). However, mean total patient spending increased by 163%. Beneficiaries switching GH brands in the year ranged 1.4-3.6% in 2001-2007 and 5.1-8.8% afterwards, with 25.6% switching in 2009 and 13.9% switching in 2015. Main conclusions The FDA ISS approval was not a watershed event in the steady increase in GH utilization by U.S. youth. Progressive restrictions on coverage and formulary preference coverage strategies appear to have succeeded in lowering total expenditures and insurer burden of GH treatment per beneficiary. However, those savings were not passed on to patients, who bore greater burdens financially and from brand switches.
Funding Information
  • Children’s Hospital of Philadelphia (Pediatric Academic Enrichment Fund Award)

This publication has 14 references indexed in Scilit: